NCT00515619

Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

An International Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral Lacosamide (SPM 927) in Patients With Partial Seizures

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 376 (actual)
• Sponsor: UCB Pharma · Industry
• Sex: All
• Age: 16 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this trial is to determine safety and efficacy of Lacosamide under long term therapy.

Conditions

• Epilepsy

Interventions

Type	Name	Description
DRUG	Lacosamide	50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial

Timeline

• Start date: 2004-12-01
• Primary completion: 2010-08-01
• Completion: 2010-08-01
• First posted: 2007-08-14
• Last updated: 2017-08-28
• Results posted: 2011-09-09

Locations

54 sites across 13 countries: Australia, Croatia, Czechia, Finland, France, Germany, Hungary, Lithuania, Poland, Russia, Spain, Sweden, United Kingdom